A research team at the University of Osaka has unveiled the molecular mechanism behind genome ejection from adeno-associated virus (AAV) vectors, a crucial delivery vehicle in gene therapy. The study, ...
CNS-directed AAV gene therapy shows milder immune responses compared to systemic administration, reducing peripheral immune activation and systemic toxicities. Direct CNS delivery can bypass ...
PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in tissue-targeted AAV gene therapy, today announces the publication of a seminal research ...
GlobalData on MSN
Apertura and NIH institutes to test gene therapy for NPC1
The Ara Parseghian Medical Research Fund will provide financial backing for the multi-year research effort.
Significant variability exists in adeno-associated virus (AAV) measurement methods, especially with polymerase chain reaction-enzyme linked immunosorbent assay (PCR-ELISA), highlighting the need for ...
A new study in Human Gene Therapy describes a machine learning (ML) model that can be used as a surrogate for laborious in vitro experiments. This in silico approach aims to increase the fitness of ...
Virica Biotech and Ginkgo Bioworks Announce Partnership to Accelerate AAV Gene Therapy Manufacturing
Virica Biotech will provide a panel of their cell enhancers for use in high-throughput AAV production screening for Ginkgo’s clients. Ginkgo Bioworks will leverage their advanced screening platform ...
16d
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Detailed price information for Taysha Gene Therapies Inc (TSHA-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results